Provided by Tiger Trade Technology Pte. Ltd.

CNS Pharmaceuticals, Inc.

4.27
-0.2400-5.32%
Post-market: 4.270.00000.00%19:22 EST
Volume:31.17K
Turnover:135.07K
Market Cap:2.65M
PE:-0.19
High:4.48
Open:4.41
Low:4.26
Close:4.51
52wk High:114.00
52wk Low:4.26
Shares:620.30K
Float Shares:539.50K
Volume Ratio:1.83
T/O Rate:5.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-22.7490
EPS(LYR):-466.4490
ROE:-197.11%
ROA:-85.59%
PB:0.27
PE(LYR):-0.01

Loading ...

CNS Pharmaceuticals Inc. Outlines Strategy to Sharpen Focus, Optimize Pipeline, and Align Capital Allocation for Long-Term Value Creation

Reuters
·
Jan 27

CNS Pharmaceuticals says priority ‘is to transform’ how company operates

TIPRANKS
·
Jan 27

CNS Pharmaceuticals Inc trading halted, volatility trading pause

TIPRANKS
·
Jan 15

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM

Reuters
·
Jan 15

CNS Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CEO and President Rami Levin

Reuters
·
Jan 03

CNS Pharmaceuticals Inc - Appoints Rami Levin as CEO Effective Jan 1, 2026 - SEC Filing

THOMSON REUTERS
·
Dec 17, 2025

CNS Pharmaceuticals Inc - John Climaco Resigns as CEO and Board Member Effective Dec 16, 2025 - SEC Filing

THOMSON REUTERS
·
Dec 17, 2025

CNS Pharmaceuticals Appoints Rami Levin as CEO

Reuters
·
Dec 17, 2025

CNS Pharmaceuticals Held Annual Shareholder Meeting

Reuters
·
Nov 22, 2025

CNS Pharmaceuticals reports Q3 net loss of $3.3 million

Reuters
·
Nov 17, 2025

CNS Pharmaceuticals Unveils New Glioblastoma and Pediatric DMG Clinical Trial Results at SNO 2025

Reuters
·
Nov 10, 2025

CNS Pharmaceuticals Inc announces date for annual stockholder meeting

Reuters
·
Oct 11, 2025

CNS Pharmaceuticals Raised to Buy From Hold by Maxim Group

Dow Jones
·
Sep 12, 2025

CNS Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold

THOMSON REUTERS
·
Sep 12, 2025

Top Premarket Decliners

MT Newswires Live
·
Aug 21, 2025

CNS Pharmaceuticals Reports Q2 2025 Results: Net Loss Narrows to $2.4M, R&D Expenses Rise Slightly

Reuters
·
Aug 15, 2025

CNS Pharmaceuticals Q2 EPS $(6.42) Beats $(9.60) Estimate

Benzinga
·
Aug 15, 2025

CNS Pharmaceuticals Inc. to Present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Reuters
·
Aug 14, 2025

CNS Pharmaceuticals Inc expected to post a loss of $9.60 a share - Earnings Preview

Reuters
·
Aug 09, 2025